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Abstract
Autologous hematopoietic stem cell transplantation (autoHSCT) requires collection of sufficient number of hematopoietic stem cells. The goal of this study was to evaluate efficacy of plerixafor used in patients with lymphoid malignancies failing conventional stem cell mobilization. This was a prospective, non-interventional study. All consecutive patients (n = 109) treated with plerixafor in 11 centers were reported. The drug was used either in case of previous mobilization failure (n = 67) or interventionally, in case of insufficient CD34
+ cell output during current mobilization (n = 42). Successful mobilization was defined as resulting in collection of ≥ 2 × 10 6 CD34 + cells/kg for single autoHSCT or ≥ 4 × 10 6 CD34 + cells/kg for double procedure. The overall rate of successful mobilization was 55% (55% for single and 56% for double autoHSCT). The median total number of collected CD34 + cells/kg was 2.4 (range, 0-11.5) for patients intended for a single transplantation while 4.0 (0.6-16.9) for double procedure. 
Plerixafor use and leukaphereses
In line with the Polish regulations regarding reimbursement of plerixafor by public sources the drug could be used in the following cases: 
Study endpoints
The percentage of patients with successful mobilization i.e. who collected ≥ 2 × 10 6 CD34 + cells/kg for single autoHSCT or ≥ 4 × 10 6 CD34 + cells/kg for double procedure, accordingly, was the primary study end-point. The total CD34 + cell yield and the number of leukaphereses needed to obtain the transplant material, as well as fold increase of CD34 + count in peripheral blood before and after 1st
plerixafor administration were secondary end-points.
Statistical methods
The statistical analysis included data from all enrolled patients. Chi 
Results

Patient characteristics
Between 
Mobilization with plerixafor
There were 69/109 (63%) participants who received plerixafor in the 
Efficacy of mobilization using plerixafor
In 38 (35%) patients the required number of CD34 + cells/kg were collected with a maximum of two plerixafor administrations while the additional 22 patients (20%) requried the subsequent doses.
The total sucess rate was 55% (55% for patients intended for single 
Factors affecting efficacy of mobilization with the use of plerixafor
A univariate analysis was performed to evaluate associations of potential prognostic factors with the rate of successful mobilization.
The following factors were analyzed: age, performance status, type of mobilization, diagnosis, number of preceding lines of chemotherapy, preceding radiotherapy, preceding autoHSCT. However, differences for none of the variables were statistically significant (data not shown).
Efficacy of mobilization according to physisian's assessment
Investigators were asked for their subjective opinion regarding the efficacy of plerixafor used for stem cell mobilization. Most physicians stated that it enabled either a single or tandem transplantation.
According to 25% of investigators plerixafor shortened the apheresis procedure and according to 23% of physicians it allowed diminishing intensity of chemotherapy (Tab. V).
Toxicity and supportive care
Twenty-two adverse events (AE) were reported in 12 patients according to World Health Organization (WHO) Toxicity Grading
Scale. There were 7 AEs of grade 3-4, however, none of them was assessed to be associated with administration of plerixafor. Ten AEs were evaluated as related to plerixafor, most frequently diarrhoea (n = 3), abominal pain (n = 2) and muscular pain (n = 2) (Tab. VI).
Discussion
This is the first prospective multicenter observational study to In many studies, clinical benefits of engraftment rate and overall survival have been analyzed and point toward a correlation between higher CD34 + cell dose and faster engraftment and platelet recovery [4, 6, 7] . The search for an optimal mobilization regimen and efficient collection even in very poor mobilizers was a subject of series of is useful to achieve efficient collection even in very poor mobilizers as a hope for patients with diminished hematopoietic function [13] [14] [15] [16] [17] 19] . Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in MM and lymphoma patients have been discussed and agreed by many authors [18, 31, 32] . There are several studies regarding the additional cost related to the use of plerixafor under different protocols. These costs depend on local fees and prices as well as the perspective adopted in the cost analysis;
however, most studies concluded that the use of plerixafor led to an additional but acceptable cost, given the clinical benefit obtained [31] [32] [33] [34] . According to the current practice, the option of in-hospital or home administration for plerixafor injection to poor mobilizers has The analysis was restricted to 81 patients with available data. 
Body weight loss --1 (1%) -1 (1%) No no adverse consequences on subsequent hematopoietic stem cell harvest [33] .
In our study, despite a heavily pretreated and poorly mobilizing patient population, administration of plerixafor allowed the collection of a sufficient number for stem cells in 55% of patients referred for single autoHSCT and 56% of those planned for double procedure.
We were unable to distinguish a subgroup of patients who may be at risk of failure after plerixafor-based mobilization. The effect was comparable regardless of laboratory parameters including the number of circulating CD34 + cells prior to drug administration. In addition, none of the clinical features was associated with the risk of mobilization failure in an univariate analysis. Finally, the therapy was well tolerated with no serious adverse events relative to administration of plerixafor. These findings should be useful to create a national guideline regarding strategies to optimize stem cell mobilization.
Conclusion
Plerixafor treatment is a valuable therapeutic option for NHL, HL, MM patients scheduled for autoHSCT with risk factors for mobilization failure, with minor toxicity and very good efficacy.
